How maintenance rituximab therapy improves outcomes for mantle cell lymphoma patients who respond to bendamustine + rituximab induction therapy without autologous transplant.
Clinical trial results of parsaclisib for relapsed or refractory mantle cell lymphoma (R/R MCL) in BTK inhibitor-naïve patients from the CITADEL-205 study.